Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus

M. A. Vickers, Ramgopal Satyanarayana

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in 'general' and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built.

Original languageEnglish
Pages (from-to)466-471
Number of pages6
JournalInternational Journal of Impotence Research
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Phosphodiesterase 5 Inhibitors
Erectile Dysfunction
Diabetes Mellitus
Clinical Trials
Population
Therapeutics
Safety
Vardenafil Dihydrochloride
Sildenafil Citrate
Tadalafil

Keywords

  • Diabetes mellitus
  • Erectile dysfunction
  • Phosphodiesterase inhibitor
  • Sildenafil
  • Tadalafil
  • Vardenafil

ASJC Scopus subject areas

  • Urology

Cite this

@article{e1bd8d1282fd414489a1d9bda7ff6548,
title = "Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus",
abstract = "Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56{\%} vs 84{\%} in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in 'general' and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built.",
keywords = "Diabetes mellitus, Erectile dysfunction, Phosphodiesterase inhibitor, Sildenafil, Tadalafil, Vardenafil",
author = "Vickers, {M. A.} and Ramgopal Satyanarayana",
year = "2002",
month = "12",
day = "1",
doi = "10.1038/sj.ijir.3900910",
language = "English",
volume = "14",
pages = "466--471",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus

AU - Vickers, M. A.

AU - Satyanarayana, Ramgopal

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in 'general' and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built.

AB - Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in 'general' and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built.

KW - Diabetes mellitus

KW - Erectile dysfunction

KW - Phosphodiesterase inhibitor

KW - Sildenafil

KW - Tadalafil

KW - Vardenafil

UR - http://www.scopus.com/inward/record.url?scp=0036934069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036934069&partnerID=8YFLogxK

U2 - 10.1038/sj.ijir.3900910

DO - 10.1038/sj.ijir.3900910

M3 - Article

C2 - 12494279

AN - SCOPUS:0036934069

VL - 14

SP - 466

EP - 471

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - 6

ER -